Novartis AG banner

Novartis AG
OTC:NVSEF

Watchlist Manager
Novartis AG Logo
Novartis AG
OTC:NVSEF
Watchlist
Price: 156.65 USD 11.11%
Market Cap: $322.1B

Wall St Price Targets

NVSEF Price Targets Summary
Novartis AG

Wall Street analysts forecast NVSEF stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NVSEF is 155 USD with a low forecast of 117.83 USD and a high forecast of 185.04 USD.

Lowest Forecast
Price Target
117.83 USD
25% Downside
Average Forecast
Price Target
155 USD
1% Downside
Highest Forecast
Price Target
185.04 USD
18% Upside
Novartis AG Competitors:
Price Targets
FCNCA
First Citizens BancShares Inc (Delaware)
7% Upside
IMRX
Immuneering Corp
291% Upside

Revenue
Forecast

0% / Year
Past Growth
5% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
0% / Year
Past Growth
5% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 0%. The projected CAGR for the next 3 years is 5%.

Gross Profit
Forecast

1% / Year
Past Growth
7% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
1% / Year
Past Growth
7% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 1%. The projected CAGR for the next 3 years is 7%.

Operating Income
Forecast

4% / Year
Past Growth
9% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
4% / Year
Past Growth
9% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 4%. The projected CAGR for the next 3 years is 9%.

Pre-Tax Income
Forecast

3% / Year
Past Growth
12% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
3% / Year
Past Growth
12% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 3%. The projected CAGR for the next 3 years is 12%.

Net Income
Forecast

3% / Year
Past Growth
12% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
3% / Year
Past Growth
12% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 3%. The projected CAGR for the next 3 years is 12%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is NVSEF's stock price target?
Price Target
155 USD

According to Wall Street analysts, the average 1-year price target for NVSEF is 155 USD with a low forecast of 117.83 USD and a high forecast of 185.04 USD.

What is the Revenue forecast for Novartis AG?
Projected CAGR
5%

Over the last 13 years, the compound annual growth rate for Revenue has been 0%. The projected CAGR for the next 3 years is 5%.

What is the Gross Profit forecast for Novartis AG?
Projected CAGR
7%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 1%. The projected CAGR for the next 3 years is 7%.

What is the Operating Income forecast for Novartis AG?
Projected CAGR
9%

Over the last 13 years, the compound annual growth rate for Operating Income has been 4%. The projected CAGR for the next 3 years is 9%.

What is the Pre-Tax Income forecast for Novartis AG?
Projected CAGR
12%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 3%. The projected CAGR for the next 3 years is 12%.

What is the Net Income forecast for Novartis AG?
Projected CAGR
12%

Over the last 13 years, the compound annual growth rate for Net Income has been 3%. The projected CAGR for the next 3 years is 12%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett